Clinical Trial TitlePhase 2 trial of response-based radiation therapy for patients with localized central nervous system germ cell tumors (CNS GCT).
Clinical Trial Protocol Description:
To determine, as measured by the 3-year progression free survival rate and patterns of failure, whether simplified chemotherapy followed by dose-reduced radiation therapy is effective for treating children and young adults (ages 3 to < 21 years) with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGI3) < 50miU/ml.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are between 3 and 21 years of age at the time of study enrollment.
- Have been newly diagnosed with localized primary CNS NGGCT (Stratum 1) or localized primary CNS germinoma (Stratum 2). Germ cell tumors located in the suprasellar pineal, bifocal (pineal + suprasellar) and ventricles are eligible. Tumors present in the above mentioned locations and with unifocal parenchymal extension are eligible.
This is a partial list of eligibility requirements.
Clinical Trial Investigator
Mary Lou Schmidt, MD
RUSH Cancer Center
1520 W Harrison St
Joan and Paul Rubschlager Building
Chicago, IL 60607